← Back to Search

Device

Randomized Study of Silq Urinary Catheter

N/A
Waitlist Available
Research Sponsored by Hydrophilix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Requiring indwelling 16Fr Foley catheter for at least 7 days
Male or female age ≥ 18 years old;
Must not have
Any other infection being treated with antibiotics at the time of catheter implantation
Females who are pregnant or breastfeeding or who plan to become pregnant during the study.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 to 7 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a special silicone urinary catheter to see if it reduces bacterial buildup in patients who need catheters for extended periods. The goal is to prevent infections and other complications.

Who is the study for?
Adults aged 18 or older who need a long-term Foley catheter (16Fr size) for at least 7 days can join. They must be able to follow the study's procedures and give informed consent. People with allergies to catheter materials, urethral strictures, current UTI or other infections treated with antibiotics, needing bladder irrigation during the study, pregnant or breastfeeding women, and those in another trial cannot participate.
What is being tested?
The trial is testing if the Silq ClearTract™ Silicone Foley Catheter is better at preventing biofilm formation compared to standard urinary catheters in patients requiring long-term use. Participants will be randomly assigned to receive either the Silq catheter or a commercial one.
What are the potential side effects?
Potential side effects may include discomfort during insertion or wear of the catheter, allergic reactions if sensitive to silicone or other materials used in the device, urinary tract infection symptoms like burning sensation and foul-smelling urine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I need a specific catheter in place for at least a week.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am on antibiotics for an infection during my catheter placement.
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant during the study.
Select...
I am currently being treated for a UTI with symptoms like fever or burning sensation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 to 7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 to 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biofilm formation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Silq ClearTract™ 100% Silicone 2-Way Foley CatheterActive Control1 Intervention
Up to 82 subjects
Group II: Silicone-coated Latex 2-Way Foley catheterActive Control1 Intervention
Up to 82 subjects
Group III: Silver-coated Latex 2-Way Foley CatheterActive Control1 Intervention
Up to 82 subjects

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for biofilm formation include the use of materials that resist bacterial adhesion, such as silicone, and the application of antimicrobial agents. Silicone catheters, like the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter, reduce biofilm formation by providing a smooth surface that minimizes bacterial attachment and colonization. This is crucial for patients because biofilms can lead to persistent infections and complications, especially in long-term catheter use. Antimicrobial coatings or irrigations further inhibit bacterial growth and biofilm development, enhancing the effectiveness of the silicone material. These strategies are essential for preventing infections and improving patient outcomes.

Find a Location

Who is running the clinical trial?

HydrophilixLead Sponsor
Silq Technologies CorporationLead Sponsor
1 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

Silq ClearTract™ 100% Silicone 2-Way Foley Catheter (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04841226 — N/A
Biofilm Formation Research Study Groups: Silq ClearTract™ 100% Silicone 2-Way Foley Catheter, Silicone-coated Latex 2-Way Foley catheter, Silver-coated Latex 2-Way Foley Catheter
Biofilm Formation Clinical Trial 2023: Silq ClearTract™ 100% Silicone 2-Way Foley Catheter Highlights & Side Effects. Trial Name: NCT04841226 — N/A
Silq ClearTract™ 100% Silicone 2-Way Foley Catheter (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04841226 — N/A
~40 spots leftby Dec 2025